ADAMTS13 recovery in caplacizumab-treated TTP; inhibition of venetoclax-resistant BCL2 variants with sonrotoclax; genomic insights from Castleman disease in twins
In this week's epside we'll learn about ADAMTS recovery after caplacizumab therapy in patients with immune thrombotic thrombocytopenic purpura. Then, we'll hear about preclinical characterization of sonrotoclax, a potential second-generation BCL2 inhibitor. Finally we'll hear about new insights into the etiology of Castleman disease where researchers describe the unusual occurrence of idiopathic multicentric Castleman disease in identical twins.
Featured Articles:
ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy
Sonrotoclax overcomes BCL2 G101V…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.